SEC Foi	rm 4 FORM	4 (JNITE) STA	TES	SEC	URITI	ES	AND	E	ХСНА	NG	ЕC	OMM	ISSION				
			Washington, D.C. 20549													OMB APPROVAL			
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).			STA		ed pursua	DURSUANT OF CHANGES IN BENEFICIAL OWNE pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									SHIP	Estim	OMB Number: 323 Estimated average burden hours per response:		
1. Name and Address of Reporting Person [*] Kronenfeld Mark A.					2. Issuer Name and Ticker or Trading Symbol <u>Pacira BioSciences, Inc.</u> [PCRX]									(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title Other (specify below) below)				wner
(Last) (First) (Middle) C/O PACIRA BIOSCIENCES, INC. 5 SYLVAN WAY, SUITE 300					3. Date of Earliest Transaction (Month/Day/Year) 06/09/2020														specify
(Street)		4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person							
PARSIP: (City)	PANY N	07054 (Zip)											Form filed by More than One Reporting Person						
		Tab	le I - No	n-Deriv	vative \$	Secur	ities A	cqui	ired, D	isp	oosed o	of, o	r Bei	neficial	ly Owned	d			
1. Title of Security (Instr. 3) 2. Tran Date				2. Trans Date	th/Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)		d (A) or	5. Amou Securitie Benefici	nt of es ally -ollowing	Form (D) o	vnership n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code V	'	Amount		(A) or (D)	Price	Transac (Instr. 3	tion(s)			(
Common Stock 06/09/					9/2020	2020			Α		1,260	50 ⁽¹⁾ A		\$0.0	0 15,671			D	
		T									osed of, onverti				/ Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemo Execution if any (Month/Da	Date,	4. Transact Code (In: 8)	tion of str. D S A (A D of of	of E		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securitie Beneficia Owned Following Reported Transacti (Instr. 4)	e s dly g	Ownershij Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownershi t (Instr. 4)
				ľ										Amount or Number					

Date Exercisable

06/09/2021

1. Represents restricted stock units that vest on June 3, 2021, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Expiration Date

06/09/2030

Title

in-Fact

Common Stock

** Signature of Reporting Person Date

/s/ Kristen Williams, Attorney-06/11/2020

of Shares

8,027

\$<mark>0.00</mark>

8,027

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

06/09/2020

Stock Option (Right to

Buy)

Remarks:

\$47.65

Explanation of Responses:

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code v

A

(A)

8,027

(D)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.